Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;97(8):1075-1085.
doi: 10.1002/ajh.26556. Epub 2022 Apr 12.

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

Elena Inzoli  1   2 , Andrea Aroldi  1   2 , Rocco Piazza  1   2 , Carlo Gambacorti-Passerini  1   2
Affiliations
Review

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

Elena Inzoli et al. Am J Hematol. 2022 Aug.

Abstract

TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and monitoring. Clinical and biological factors associated with better outcomes do not yet offer a precise stratification of patients according to their risk of relapse. This article aims at reviewing the leading studies present in the field in order to define eligibility criteria for discontinuation and predictors of success.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Summary of possible predictors of TKI discontinuation according to the different studies cited in the paper [Color figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Gambacorti‐Passerini C. Part I: milestones in personalised medicine‐imatinib. Lancet Oncol. 2008;9(6):600. doi:10.1016/S1470-2045(08)70152-9 - DOI - PubMed
    1. Gambacorti‐Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553‐561. doi:10.1093/jnci/djr060 - DOI - PubMed
    1. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851‐2857. doi:10.1200/JCO.2015.66.2866 - DOI - PubMed
    1. Efficace F, Baccarani M, Breccia M, et al. Health‐related quality of life in chronic myeloid leukemia patients receiving long‐term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554‐4560. doi:10.1182/blood-2011-04-347575 - DOI - PubMed
    1. Phillips KM, Pinilla‐Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21(4):1097‐1103. doi:10.1007/s00520-012-1630-5 - DOI - PubMed

Publication types

MeSH terms

Substances